ClinicalTrials.gg
CompletedNCT03760146Updated Dec 2, 2021Results posted

Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

A Phase 3 interventional study of 20vPnC and 13vPnC in Pneumococcal Disease, sponsored by Pfizer. Completed at 68 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-02.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,902
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
Largest of 19
3,902 · median 668
Started
2018
the only one that year
Phase 3
14 of 19
1 open now
Registered
1st of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one has the largest enrollment, is the only one that started in 2018, is one of 14 in phase 3, and was the 1st registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
  2. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of product.
  3. Negative urine pregnancy test at Visit1 for all subjects who are of .

Exclusion criteria

Exclusion Criteria:

  1. Previous vaccination with any licensed or pneumococcal vaccine, or planned receipt through study participation.
  2. History of microbiologically proven invasive disease caused by S pneumoniae.
  3. Serious chronic disorder including , severe (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
  4. Pregnant female subjects or breastfeeding female subjects.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,902 participants (actual)

Study arms

  • Experimental
    60 years and above 20vPnC/Saline

    20vPnC and saline

    Biological: 20vPnC · Other: Saline

  • Active comparator
    60 years and above 13vPnC/PPSV23

    13vPnC and PPSV23

    Biological: 13vPnC · Biological: PPSV23

  • Experimental
    50 through 59 years of age 20vPnC

    20vPnC

    Biological: 20vPnC

  • Experimental
    18 through 49 years of age 20vPnC

    20vPnC

    Biological: 20vPnC

  • Active comparator
    50 through 59 years of age 13vPnC

    13vPnC

    Biological: 13vPnC

  • Active comparator
    18 through 49 years of age 13vPnC

    13vPnC

    Biological: 13vPnC

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 10 Days After Vaccination in All Cohorts

    Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

    Time frame: Within 10 days after 20vPnC or 13vPnC

  2. Percentage of Participants With Systemic Events Within 7 Days After Vaccination in All Cohorts

    Systemic events fever, fatigue, headache, muscle pain and joint pain were recorded by using an electronic diary. Fever was defined as greater than or equal to (\>=) 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity).

    Time frame: Within 7 days after 20vPnC or 13vPnC

  3. Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination in All Cohorts

    An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship with the treatment.

    Time frame: Within 1 month after 20vPnC or 13vPnC

  4. Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination in All Cohorts

    An SAE was any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect or that is considered to be an important medical event.

    Time frame: Within 6 months after 20vPnC or 13vPnC

  5. Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination in All Cohorts

    An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects.

    Time frame: Within 6 months after 20vPnC or 13vPnC

  6. Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population

    OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA geometric mean and 2-sided 95% CIs were calculated.

    Time frame: 1 month after Vaccination 1

  7. Pneumococcal OPA GMTs for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population (E7-AIP)

    OPA GMTs were determined for serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA geometric mean and 2-sided 95% CIs were calculated.

    Time frame: 1 month after Vaccination 1 in "Cohort 1: 20vPnC/Saline"; 1 month after Vaccination 2 in "Cohort 1: 13vPnC/PPSV23"

Secondary outcomes

  1. Pneumococcal OPA GMTs for the 20 Vaccines Serotypes at 1 Month After 20vPnC Vaccination in Cohort 2, 50 Through 59 Years of Age and Cohort 1, Only 60 Through 64 Years of Age: Evaluable-20 Immunogenicity Population

    OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA geometric mean and 2-sided 95% CIs were calculated.

    Time frame: 1 month after vaccination

  2. Pneumococcal OPA GMTs for the 20 Vaccines Serotypes at 1 Month After 20vPnC Vaccination in Cohort 3, 18 Through 49 Years and Cohort 1, Only 60 Through 64 Years of Age: Evaluable-20 Immunogenicity Population

    OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA geometric mean and 2-sided 95% CIs were calculated.

    Time frame: 1 month after vaccination

  3. Pneumococcal OPA Geometric Mean Fold Rises (GMFRs) for the 13 Matched Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population

    OPA GMFR is the ratio of OPA GMT, 1 month after vaccination to before vaccination OPA GMT. OPA GMFRs from before to 1 month after vaccination were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

    Time frame: Before Vaccination 1 to 1 month after Vaccination 1

  4. Pneumococcal OPA GMFRs for the Additional 7 Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population

    OPA GMFR is the ratio of OPA GMT, 1 month after vaccination to before vaccination OPA GMT. OPA GMFRs from before to 1 month after vaccination were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F.

    Time frame: From before Vaccination 1 to 1 month after Vaccination 1 in "Cohort 1: 20vPnC/Saline" or From before Vaccination 1 to 1 month after Vaccination 2 in "Cohort 1: 13vPnC/PPSV23"

  5. Pneumococcal OPA GMFRs for the 20 Vaccines Serotypes From Before Vaccination to 1 Month After Vaccination in Cohort 2 and 3: Evaluable-20 Immunogenicity Population

    OPA GMFR is the ratio of OPA GMT, 1 month after vaccination to before vaccination OPA GMT. OPA GMFRs from before to 1 month after vaccination were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

    Time frame: Before vaccination to 1 month after vaccination

  6. Percentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers to the 13 Matched Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population

    Percentage of participants with a \>=4-fold rise in serotype-specific pneumococcal OPA titers from before vaccination to 1 month after vaccination along with corresponding 2-sided 95% CIs were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

    Time frame: Before Vaccination 1 to 1 month after Vaccination 1

  7. Percentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers for the 7 Additional Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1(20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2(PPSV23) in Cohort 1:E7-AIP

    Percentage of participants with a \>=4-fold rise in serotype-specific pneumococcal OPA titers from before vaccination to 1 month after vaccination along with corresponding 2-sided 95% CIs were calculated for pneumococcal serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F.

    Time frame: Before Vaccination 1 to 1 month after Vaccination 1 for "Cohort 1: 20vPnC/Saline"; Before Vaccination 1 to 1 month after Vaccination 2 for "Cohort 1: 13vPnC/PPSV23"

  8. Percentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers for the 20 Vaccines Serotypes From Before Vaccination to 1 Month After Vaccination in Cohort 2 and 3: Evaluable-20 Immunogenicity Population

    Percentage of participants with a \>=4-fold rise in serotype-specific pneumococcal OPA titers from before vaccination to 1 month after vaccination along with corresponding 2-sided 95% CIs were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

    Time frame: Before vaccination to 1 month after vaccination

  9. Percentage of Participants With Pneumococcal OPA Titers >= Lower Limit of Quantitation (LLOQ) for the 13 Matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population

    The percentage of participants with OPA titers \>=LLOQ along with corresponding 2-sided 95% CIs were calculated 1 month after vaccination for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

    Time frame: 1 month after Vaccination 1

  10. Percentage of Participants With Pneumococcal OPA Titers >=LLOQ for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population

    The percentage of participants with OPA titers \>=LLOQ along with corresponding 2-sided 95% CIs were calculated 1 month after vaccination for pneumococcal serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F.

    Time frame: 1 month after Vaccination 1 in "Cohort 1: 20vPnC/Saline" or 1 month after Vaccination 2 in "Cohort 1: 13vPnC/PPSV23"

  11. Percentage of Participants With Pneumococcal OPA Titers >=LLOQ for the 20 Vaccines Serotypes at 1 Month After Vaccination (20vPnC) in Cohort 2 and 3: Evaluable-20 Immunogenicity Population

    The percentage of participants with OPA titers \>=LLOQ along with corresponding 2-sided 95% CIs were calculated 1 month after vaccination for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. Data for this outcome measure were planned to be analyzed for the 20vPnC groups of Cohorts 2 and 3 only.

    Time frame: 1 month after vaccination

07

Results

Posted Dec 29, 2020

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23Cohort 2: 20vPnCCohort 2: 13vPnCCohort 3: 20vPnCCohort 3: 13vPnC
Started15141495334111336112
Evaluable 13-matched immunogenicity population143514200000
Evaluable 7-additional immunogenicity population143313830000
Vaccination 115071490334111335112
Vaccination 2146114460000
Safety population15071490334111335112
Evaluable-20 immunogenicity population946032103170
Completed14181417323109319104
Not completed9678112178
Withdrew: Adverse event1180000
Withdrew: Death100000
Withdrew: Lost to follow-up412892148
Withdrew: No longer met eligibility criteria390010
Withdrew: Protocol violation21131010
Withdrew: Withdrawal by subject19201010

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 10 Days After Vaccination in All Cohorts

Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

Time frame:
Within 10 days after 20vPnC or 13vPnC
Reported as:
Number · percentage of participants
Percentage of Participants With Local Reactions Within 10 Days After Vaccination in All Cohorts
percentage of participantsCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23Cohort 2: 20vPnCCohort 2: 13vPnCCohort 3: 20vPnCCohort 3: 13vPnC
Redness: Any7.3 (6.0 to 8.7)6.2 (5.0 to 7.6)8.2 (5.4 to 11.6)5.4 (2.0 to 11.4)9.0 (6.1 to 12.5)9.8 (5.0 to 16.9)
Redness: Mild3.7 (2.8 to 4.8)3.8 (2.9 to 4.9)5.1 (3.0 to 8.1)2.7 (0.6 to 7.7)3.0 (1.4 to 5.4)5.4 (2.0 to 11.3)
Redness: Moderate2.8 (2.0 to 3.8)2.2 (1.5 to 3.1)2.7 (1.3 to 5.1)2.7 (0.6 to 7.7)5.4 (3.2 to 8.4)4.5 (1.5 to 10.1)
Redness: Severe0.8 (0.4 to 1.4)0.2 (0.0 to 0.6)0.3 (0.0 to 1.7)0 (0.0 to 3.3)0.6 (0.1 to 2.1)0 (0.0 to 3.2)
Swelling: Any7.5 (6.2 to 9.0)8.0 (6.6 to 9.5)8.8 (5.9 to 12.3)10.8 (5.7 to 18.1)11.6 (8.4 to 15.6)12.5 (7.0 to 20.1)
Swelling: Mild4.8 (3.8 to 6.0)4.9 (3.8 to 6.1)5.7 (3.5 to 8.8)7.2 (3.2 to 13.7)7.2 (4.6 to 10.5)8.9 (4.4 to 15.8)
Swelling: Moderate2.4 (1.7 to 3.3)2.8 (2.0 to 3.8)3.0 (1.5 to 5.5)3.6 (1.0 to 9.0)4.5 (2.5 to 7.3)3.6 (1.0 to 8.9)
Swelling: Severe0.3 (0.1 to 0.8)0.3 (0.1 to 0.7)0 (0.0 to 1.1)0 (0.0 to 3.3)0 (0.0 to 1.1)0 (0.0 to 3.2)
Pain at the injection site: Any55.4 (52.9 to 57.9)54.1 (51.6 to 56.7)72.5 (67.4 to 77.2)69.4 (59.9 to 77.8)81.2 (76.6 to 85.2)82.1 (73.8 to 88.7)
Pain at the injection site: Mild45.3 (42.8 to 47.9)44.6 (42.1 to 47.2)53.5 (47.9 to 58.9)52.3 (42.6 to 61.8)42.7 (37.3 to 48.2)52.7 (43.0 to 62.2)
Pain at the injection site: Moderate9.9 (8.4 to 11.5)9.2 (7.7 to 10.8)17.8 (13.9 to 22.4)16.2 (9.9 to 24.4)38.2 (33.0 to 43.6)28.6 (20.4 to 37.9)
Pain at the injection site: Severe0.2 (0.0 to 0.6)0.3 (0.1 to 0.8)1.2 (0.3 to 3.1)0.9 (0.0 to 4.9)0.3 (0.0 to 1.7)0.9 (0.0 to 4.9)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination in All Cohorts

Systemic events fever, fatigue, headache, muscle pain and joint pain were recorded by using an electronic diary. Fever was defined as greater than or equal to (\>=) 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity).

Time frame:
Within 7 days after 20vPnC or 13vPnC
Reported as:
Number · percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination in All Cohorts
percentage of participantsCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23Cohort 2: 20vPnCCohort 2: 13vPnCCohort 3: 20vPnCCohort 3: 13vPnC
Fever: >=38.0 degree C0.9 (0.5 to 1.6)0.8 (0.4 to 1.4)1.5 (0.5 to 3.5)0.9 (0.0 to 4.9)1.2 (0.3 to 3.0)1.8 (0.2 to 6.3)
Fever: >=38.0 degree C to 38.4 degree C0.3 (0.1 to 0.7)0.4 (0.1 to 0.9)0.6 (0.1 to 2.2)0.9 (0.0 to 4.9)0.6 (0.1 to 2.1)0 (0.0 to 3.2)
Fever: >38.4 degree C to 38.9 degree C0.3 (0.1 to 0.7)0.2 (0.0 to 0.6)0.3 (0.0 to 1.7)0 (0.0 to 3.3)0.3 (0.0 to 1.7)0 (0.0 to 3.2)
Fever: >38.9 degree C to 40.0 degree C0.0 (0.0 to 0.4)0 (0.0 to 0.2)0.3 (0.0 to 1.7)0 (0.0 to 3.3)0.3 (0.0 to 1.7)1.8 (0.2 to 6.3)
Fever: >40.0 degree C0.3 (0.1 to 0.8)0.2 (0.0 to 0.6)0.3 (0.0 to 1.7)0 (0.0 to 3.3)0 (0.0 to 1.1)0 (0.0 to 3.2)
Fatigue: Any30.2 (27.9 to 32.6)30.7 (28.3 to 33.1)39.3 (34.0 to 44.8)36.0 (27.1 to 45.7)42.7 (37.3 to 48.2)43.8 (34.4 to 53.4)
Fatigue: Mild16.1 (14.3 to 18.1)17.5 (15.6 to 19.6)21.1 (16.9 to 25.9)18.0 (11.4 to 26.4)18.8 (14.8 to 23.4)20.5 (13.5 to 29.2)
Fatigue: Moderate12.8 (11.2 to 14.6)11.9 (10.3 to 13.7)17.2 (13.3 to 21.7)15.3 (9.2 to 23.4)22.1 (17.8 to 26.9)19.6 (12.7 to 28.2)
Fatigue: Severe1.2 (0.7 to 1.9)1.2 (0.7 to 1.9)0.9 (0.2 to 2.6)2.7 (0.6 to 7.7)1.8 (0.7 to 3.9)3.6 (1.0 to 8.9)
Headache: Any21.5 (19.5 to 23.7)23.3 (21.1 to 25.5)32.3 (27.3 to 37.7)36.0 (27.1 to 45.7)38.8 (33.6 to 44.3)33.9 (25.3 to 43.5)
Headache: Mild15.5 (13.7 to 17.4)17.0 (15.1 to 19.0)20.5 (16.3 to 25.3)21.6 (14.4 to 30.4)21.5 (17.2 to 26.3)16.1 (9.8 to 24.2)
Headache: Moderate5.4 (4.3 to 6.6)5.9 (4.8 to 7.3)10.9 (7.7 to 14.7)13.5 (7.8 to 21.3)14.6 (11.0 to 18.9)17.0 (10.5 to 25.2)
Headache: Severe0.7 (0.3 to 1.2)0.3 (0.1 to 0.8)0.9 (0.2 to 2.6)0.9 (0.0 to 4.9)2.7 (1.2 to 5.0)0.9 (0.0 to 4.9)
Muscle pain: Any39.1 (36.6 to 41.6)37.3 (34.8 to 39.8)49.8 (44.3 to 55.4)49.5 (39.9 to 59.2)66.6 (61.2 to 71.6)74.1 (65.0 to 81.9)
Muscle pain: Mild28.9 (26.6 to 31.3)26.8 (24.6 to 29.2)33.8 (28.8 to 39.2)31.5 (23.0 to 41.0)36.4 (31.3 to 41.8)42.0 (32.7 to 51.7)
Muscle pain: Moderate9.8 (8.3 to 11.4)10.0 (8.5 to 11.6)15.4 (11.7 to 19.8)17.1 (10.6 to 25.4)29.0 (24.2 to 34.1)31.3 (22.8 to 40.7)
Muscle pain: Severe0.4 (0.1 to 0.9)0.5 (0.2 to 1.0)0.6 (0.1 to 2.2)0.9 (0.0 to 4.9)1.2 (0.3 to 3.0)0.9 (0.0 to 4.9)
Joint pain: Any12.6 (11.0 to 14.4)13.7 (12.0 to 15.5)15.4 (11.7 to 19.8)20.7 (13.6 to 29.5)13.4 (10.0 to 17.6)17.9 (11.3 to 26.2)
Joint pain: Mild6.9 (5.7 to 8.3)7.1 (5.9 to 8.6)10.6 (7.5 to 14.4)12.6 (7.1 to 20.3)6.3 (3.9 to 9.4)8.9 (4.4 to 15.8)
Joint pain: Moderate5.4 (4.3 to 6.6)6.3 (5.2 to 7.7)4.8 (2.8 to 7.7)7.2 (3.2 to 13.7)7.2 (4.6 to 10.5)8.0 (3.7 to 14.7)
Joint pain: Severe0.3 (0.1 to 0.8)0.2 (0.0 to 0.6)0 (0.0 to 1.1)0.9 (0.0 to 4.9)0 (0.0 to 1.1)0.9 (0.0 to 4.9)
PrimaryPercentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination in All Cohorts

An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship with the treatment.

Time frame:
Within 1 month after 20vPnC or 13vPnC
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination in All Cohorts
percentage of participantsCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23Cohort 2: 20vPnCCohort 2: 13vPnCCohort 3: 20vPnCCohort 3: 13vPnC
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination in All Cohorts9.8 (8.4 to 11.4)11.1 (9.6 to 12.8)10.2 (7.2 to 13.9)8.1 (3.8 to 14.8)15.2 (11.6 to 19.5)11.6 (6.3 to 19.0)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination in All Cohorts

An SAE was any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect or that is considered to be an important medical event.

Time frame:
Within 6 months after 20vPnC or 13vPnC
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination in All Cohorts
percentage of participantsCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23Cohort 2: 20vPnCCohort 2: 13vPnCCohort 3: 20vPnCCohort 3: 13vPnC
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination in All Cohorts2.4 (1.7 to 3.3)1.9 (1.3 to 2.8)0.3 (0.0 to 1.7)0.9 (0.0 to 4.9)0.6 (0.1 to 2.1)0.9 (0.0 to 4.9)
PrimaryPercentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination in All Cohorts

An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects.

Time frame:
Within 6 months after 20vPnC or 13vPnC
Reported as:
Number · percentage of participants
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination in All Cohorts
percentage of participantsCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23Cohort 2: 20vPnCCohort 2: 13vPnCCohort 3: 20vPnCCohort 3: 13vPnC
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination in All Cohorts2.3 (1.6 to 3.1)2.3 (1.6 to 3.3)1.5 (0.5 to 3.5)0.9 (0.0 to 4.9)1.5 (0.5 to 3.4)1.8 (0.2 to 6.3)
PrimaryPneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population

OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA geometric mean and 2-sided 95% CIs were calculated.

Time frame:
1 month after Vaccination 1
Reported as:
Geometric mean · titer
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population
titerCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23
Serotype 1123.4 (112.3 to 135.5)153.8 (140.2 to 168.8)
Serotype 340.7 (38.0 to 43.6)47.8 (44.7 to 51.2)
Serotype 4508.7 (456.5 to 566.9)626.9 (563.5 to 697.4)
Serotype 591.6 (83.4 to 100.5)109.7 (100.1 to 120.3)
Serotype 6A889.0 (795.0 to 994.1)1165.1 (1043.3 to 1301.0)
Serotype 6B1115.2 (1003.1 to 1239.8)1341.3 (1208.5 to 1488.8)
Serotype 7F968.8 (887.0 to 1058.3)1129.2 (1034.7 to 1232.4)
Serotype 9V1455.5 (1317.5 to 1608.0)1567.8 (1420.5 to 1730.5)
Serotype 14746.7 (679.0 to 821.2)746.7 (679.8 to 820.1)
Serotype 18C1252.6 (1123.1 to 1397.0)1482.3 (1330.5 to 1651.5)
Serotype 19A517.9 (472.2 to 568.0)645.3 (588.9 to 707.1)
Serotype 19F265.8 (240.2 to 294.1)333.3 (301.5 to 368.3)
Serotype 23F276.5 (242.5 to 315.2)335.1 (294.4 to 381.4)
Statistical analysis
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.80 · 95% CI 0.71 to 0.90
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.85 · 95% CI 0.78 to 0.93
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.81 · 95% CI 0.71 to 0.93
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.83 · 95% CI 0.74 to 0.94
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.76 · 95% CI 0.66 to 0.88
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.83 · 95% CI 0.73 to 0.95
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.86 · 95% CI 0.77 to 0.96
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.93 · 95% CI 0.82 to 1.05
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 1.00 · 95% CI 0.89 to 1.13
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.85 · 95% CI 0.74 to 0.97
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.80 · 95% CI 0.71 to 0.90
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.80 · 95% CI 0.70 to 0.91
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.83 · 95% CI 0.70 to 0.97
PrimaryPneumococcal OPA GMTs for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population (E7-AIP)

OPA GMTs were determined for serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA geometric mean and 2-sided 95% CIs were calculated.

Time frame:
1 month after Vaccination 1 in "Cohort 1: 20vPnC/Saline"; 1 month after Vaccination 2 in "Cohort 1: 13vPnC/PPSV23"
Reported as:
Geometric mean · titer
Pneumococcal OPA GMTs for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population (E7-AIP)
titerCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23
Serotype 8465.6 (422.5 to 513.1)848.1 (769.1 to 935.2)
Serotype 10A2007.6 (1808.0 to 2229.1)1079.9 (972.1 to 1199.7)
Serotype 11A4426.8 (3965.5 to 4941.8)2534.9 (2276.8 to 2822.3)
Serotype 12F2538.7 (2255.3 to 2857.7)1716.6 (1521.8 to 1936.3)
Serotype 15B2398.2 (2090.6 to 2751.2)768.5 (669.7 to 881.9)
Serotype 22F3666.2 (3244.4 to 4143.0)1846.2 (1636.6 to 2082.6)
Serotype 33F5125.9 (4611.3 to 5698.0)3720.6 (3356.2 to 4124.6)
Statistical analysis
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 0.55 · 95% CI 0.49 to 0.62
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 1.86 · 95% CI 1.63 to 2.12
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 1.75 · 95% CI 1.52 to 2.01
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 1.48 · 95% CI 1.27 to 1.72
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 3.12 · 95% CI 2.62 to 3.71
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 1.99 · 95% CI 1.70 to 2.32
  • Cohort 1: 20vPnC/Saline vs Cohort 1: 13vPnC/PPSV23 · Ratio of gmts: 1.38 · 95% CI 1.21 to 1.57
SecondaryPneumococcal OPA GMTs for the 20 Vaccines Serotypes at 1 Month After 20vPnC Vaccination in Cohort 2, 50 Through 59 Years of Age and Cohort 1, Only 60 Through 64 Years of Age: Evaluable-20 Immunogenicity Population

OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA geometric mean and 2-sided 95% CIs were calculated.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · titer
Pneumococcal OPA GMTs for the 20 Vaccines Serotypes at 1 Month After 20vPnC Vaccination in Cohort 2, 50 Through 59 Years of Age and Cohort 1, Only 60 Through 64 Years of Age: Evaluable-20 Immunogenicity Population
titerCohort 2: 20vPnCCohort 1: 20vPnC/Saline (60-64 Years of Age)
Serotype 1135.9 (113.1 to 163.4)131.8 (117.2 to 148.3)
Serotype 343.3 (38.0 to 49.4)40.9 (37.6 to 44.5)
Serotype 4633.3 (513.9 to 780.4)577.9 (505.5 to 660.6)
Serotype 584.6 (70.3 to 101.8)96.5 (85.8 to 108.6)
Serotype 6A1203.9 (968.1 to 1497.1)997.1 (866.5 to 1147.5)
Serotype 6B1502.7 (1228.2 to 1838.5)1199.0 (1054.3 to 1363.4)
Serotype 7F1047.0 (884.0 to 1240.2)1173.0 (1052.9 to 1306.9)
Serotype 9V1725.7 (1424.4 to 2090.6)1687.9 (1493.7 to 1907.3)
Serotype 14926.2 (761.8 to 1126.0)742.3 (655.8 to 840.2)
Serotype 18C1805.0 (1459.6 to 2232.2)1355.2 (1184.3 to 1550.7)
Serotype 19A618.4 (519.9 to 735.5)600.3 (537.5 to 670.6)
Serotype 19F286.7 (236.0 to 348.2)290.4 (256.4 to 329.0)
Serotype 23F549.1 (425.4 to 708.9)327.5 (278.2 to 385.6)
Serotype 8486.9 (400.6 to 591.9)502.3 (442.8 to 569.8)
Serotype 10A2520.4 (2076.0 to 3060.0)2437.0 (2149.8 to 2762.5)
Serotype 11A6416.9 (5131.9 to 8023.6)5248.9 (4564.5 to 6035.9)
Serotype 12F3445.1 (2807.8 to 4227.1)3105.2 (2722.7 to 3541.4)
Serotype 15B3355.9 (2582.0 to 4361.8)2873.7 (2438.1 to 3387.1)
Serotype 22F3808.1 (2998.2 to 4836.8)4228.4 (3629.6 to 4926.0)
Serotype 33F5571.3 (4495.7 to 6904.2)5445.2 (4749.2 to 6243.2)
Statistical analysis
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.03 · 95% CI 0.84 to 1.26
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.06 · 95% CI 0.92 to 1.22
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.10 · 95% CI 0.87 to 1.38
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 0.88 · 95% CI 0.72 to 1.07
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.21 · 95% CI 0.95 to 1.53
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.25 · 95% CI 1.00 to 1.56
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 0.89 · 95% CI 0.74 to 1.07
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.02 · 95% CI 0.83 to 1.26
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.25 · 95% CI 1.01 to 1.54
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.33 · 95% CI 1.06 to 1.68
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.03 · 95% CI 0.85 to 1.25
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 0.99 · 95% CI 0.80 to 1.22
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.68 · 95% CI 1.27 to 2.22
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 0.97 · 95% CI 0.78 to 1.20
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.03 · 95% CI 0.84 to 1.28
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.22 · 95% CI 0.96 to 1.56
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.11 · 95% CI 0.88 to 1.39
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.17 · 95% CI 0.88 to 1.56
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 0.90 · 95% CI 0.69 to 1.17
  • Cohort 2: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.02 · 95% CI 0.81 to 1.30
SecondaryPneumococcal OPA GMTs for the 20 Vaccines Serotypes at 1 Month After 20vPnC Vaccination in Cohort 3, 18 Through 49 Years and Cohort 1, Only 60 Through 64 Years of Age: Evaluable-20 Immunogenicity Population

OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA geometric mean and 2-sided 95% CIs were calculated.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · titer
Pneumococcal OPA GMTs for the 20 Vaccines Serotypes at 1 Month After 20vPnC Vaccination in Cohort 3, 18 Through 49 Years and Cohort 1, Only 60 Through 64 Years of Age: Evaluable-20 Immunogenicity Population
titerCohort 3: 20vPnCCohort 1: 20vPnC/Saline (60-64 Years of Age)
Serotype 1162.6 (135.1 to 195.6)132.0 (117.7 to 148.1)
Serotype 342.1 (36.9 to 48.1)42.0 (38.7 to 45.7)
Serotype 41966.7 (1599.5 to 2418.3)594.5 (522.9 to 675.9)
Serotype 5107.9 (89.4 to 130.1)96.9 (86.2 to 109.0)
Serotype 6A3930.5 (3176.0 to 4864.4)1022.8 (896.1 to 1167.4)
Serotype 6B4260.0 (3461.3 to 5243.1)1250.4 (1102.3 to 1418.4)
Serotype 7F1872.8 (1564.2 to 2242.4)1187.2 (1064.4 to 1324.2)
Serotype 9V6041.4 (4962.5 to 7354.9)1726.7 (1529.2 to 1949.7)
Serotype 141848.4 (1514.7 to 2255.7)772.8 (684.7 to 872.3)
Serotype 18C4460.5 (3584.6 to 5550.4)1395.3 (1220.9 to 1594.5)
Serotype 19A1415.0 (1181.8 to 1694.2)611.3 (547.8 to 682.3)
Serotype 19F654.8 (538.2 to 796.8)301.2 (266.7 to 340.1)
Serotype 23F1559.2 (1208.1 to 2012.2)324.5 (277.1 to 380.1)
Serotype 8867.0 (709.7 to 1059.2)508.1 (448.8 to 575.3)
Serotype 10A4157.3 (3410.9 to 5067.0)2569.7 (2274.0 to 2903.7)
Serotype 11A7169.3 (5735.7 to 8961.1)5419.7 (4737.7 to 6199.7)
Serotype 12F5875.4 (4719.8 to 7314.1)3074.5 (2697.9 to 3503.7)
Serotype 15B4601.0 (3487.9 to 6069.4)3019.0 (2562.8 to 3556.4)
Serotype 22F7568.2 (5927.4 to 9663.2)4482.5 (3862.7 to 5201.8)
Serotype 33F7976.9 (6341.7 to 10033.7)5693.2 (4970.1 to 6521.5)
Statistical analysis
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.23 · 95% CI 1.01 to 1.50
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.00 · 95% CI 0.87 to 1.16
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 3.31 · 95% CI 2.65 to 4.13
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.11 · 95% CI 0.91 to 1.36
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 3.84 · 95% CI 3.06 to 4.83
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 3.41 · 95% CI 2.73 to 4.26
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.58 · 95% CI 1.30 to 1.91
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 3.50 · 95% CI 2.83 to 4.33
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 2.39 · 95% CI 1.93 to 2.96
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 3.20 · 95% CI 2.53 to 4.04
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 2.31 · 95% CI 1.91 to 2.81
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 2.17 · 95% CI 1.76 to 2.68
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 4.80 · 95% CI 3.65 to 6.32
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.71 · 95% CI 1.38 to 2.12
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.62 · 95% CI 1.31 to 2.00
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.32 · 95% CI 1.04 to 1.68
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.91 · 95% CI 1.51 to 2.41
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.52 · 95% CI 1.13 to 2.05
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.69 · 95% CI 1.30 to 2.20
  • Cohort 3: 20vPnC vs Cohort 1: 20vPnC/Saline (60-64 Years of Age) · Ratio of gmts: 1.40 · 95% CI 1.10 to 1.79
SecondaryPneumococcal OPA Geometric Mean Fold Rises (GMFRs) for the 13 Matched Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population

OPA GMFR is the ratio of OPA GMT, 1 month after vaccination to before vaccination OPA GMT. OPA GMFRs from before to 1 month after vaccination were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

Time frame:
Before Vaccination 1 to 1 month after Vaccination 1
Reported as:
Geometric mean · fold rise
Pneumococcal OPA Geometric Mean Fold Rises (GMFRs) for the 13 Matched Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population
fold riseCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23
Serotype 112.6 (11.5 to 13.8)15.4 (14.1 to 16.8)
Serotype 34.8 (4.5 to 5.2)5.8 (5.4 to 6.2)
Serotype 431.2 (27.8 to 34.9)39.3 (35.1 to 44.1)
Serotype 56.1 (5.6 to 6.6)7.2 (6.6 to 7.8)
Serotype 6A34.3 (30.7 to 38.3)42.6 (38.2 to 47.5)
Serotype 6B23.8 (21.3 to 26.6)26.5 (23.7 to 29.6)
Serotype 7F12.2 (11.1 to 13.3)13.5 (12.3 to 14.8)
Serotype 9V11.0 (9.9 to 12.2)12.5 (11.3 to 13.9)
Serotype 149.3 (8.3 to 10.3)8.3 (7.4 to 9.2)
Serotype 18C33.8 (30.0 to 38.1)37.7 (33.5 to 42.5)
Serotype 19A21.0 (19.0 to 23.3)25.9 (23.3 to 28.8)
Serotype 19F8.6 (7.9 to 9.5)10.8 (9.8 to 11.9)
Serotype 23F24.9 (22.0 to 28.1)30.7 (27.1 to 34.7)
SecondaryPneumococcal OPA GMFRs for the Additional 7 Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population

OPA GMFR is the ratio of OPA GMT, 1 month after vaccination to before vaccination OPA GMT. OPA GMFRs from before to 1 month after vaccination were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F.

Time frame:
From before Vaccination 1 to 1 month after Vaccination 1 in "Cohort 1: 20vPnC/Saline" or From before Vaccination 1 to 1 month after Vaccination 2 in "Cohort 1: 13vPnC/PPSV23"
Reported as:
Geometric mean · fold rise
Pneumococcal OPA GMFRs for the Additional 7 Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population
fold riseCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23
Serotype 822.1 (20.0 to 24.5)40.4 (36.6 to 44.7)
Serotype 10A18.5 (16.5 to 20.6)10.1 (9.1 to 11.3)
Serotype 11A9.3 (8.1 to 10.7)6.0 (5.3 to 6.9)
Serotype 12F72.4 (64.2 to 81.6)47.3 (41.4 to 54.1)
Serotype 15B55.4 (47.7 to 64.4)18.2 (15.6 to 21.1)
Serotype 22F78.5 (67.3 to 91.5)37.9 (32.7 to 43.9)
Serotype 33F7.5 (6.7 to 8.5)5.7 (5.1 to 6.3)
SecondaryPneumococcal OPA GMFRs for the 20 Vaccines Serotypes From Before Vaccination to 1 Month After Vaccination in Cohort 2 and 3: Evaluable-20 Immunogenicity Population

OPA GMFR is the ratio of OPA GMT, 1 month after vaccination to before vaccination OPA GMT. OPA GMFRs from before to 1 month after vaccination were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

Time frame:
Before vaccination to 1 month after vaccination
Reported as:
Geometric mean · fold rise
Pneumococcal OPA GMFRs for the 20 Vaccines Serotypes From Before Vaccination to 1 Month After Vaccination in Cohort 2 and 3: Evaluable-20 Immunogenicity Population
fold riseCohort 2: 20vPnCCohort 3: 20vPnC
Serotype 114.4 (12.0 to 17.3)18.6 (16.0 to 21.8)
Serotype 35.1 (4.4 to 5.9)4.8 (4.2 to 5.5)
Serotype 443.4 (34.4 to 54.9)131.8 (106.4 to 163.4)
Serotype 55.9 (5.0 to 7.0)7.9 (6.7 to 9.4)
Serotype 6A50.3 (40.2 to 63.0)146.5 (120.6 to 178.0)
Serotype 6B31.7 (25.3 to 39.7)70.3 (55.7 to 88.7)
Serotype 7F12.8 (10.7 to 15.4)19.7 (16.1 to 24.3)
Serotype 9V12.1 (9.9 to 14.7)35.1 (27.9 to 44.2)
Serotype 1410.4 (8.3 to 13.0)14.6 (11.3 to 18.9)
Serotype 18C48.3 (37.9 to 61.5)111.8 (86.8 to 143.8)
Serotype 19A23.6 (19.2 to 29.1)39.1 (30.9 to 49.6)
Serotype 19F9.2 (7.6 to 11.3)17.8 (14.7 to 21.6)
Serotype 23F47.8 (37.2 to 61.3)118.2 (92.7 to 150.7)
Serotype 823.9 (19.3 to 29.6)34.6 (27.8 to 43.0)
Serotype 10A17.9 (14.2 to 22.6)22.7 (17.8 to 29.0)
Serotype 11A10.4 (7.7 to 14.2)5.2 (3.9 to 6.9)
Serotype 12F107.3 (85.8 to 134.1)171.1 (135.1 to 216.8)
Serotype 15B72.1 (51.9 to 100.1)65.0 (44.8 to 94.4)
Serotype 22F63.5 (44.8 to 90.1)69.3 (48.4 to 99.4)
Serotype 33F9.1 (7.1 to 11.7)7.5 (5.8 to 9.7)
SecondaryPercentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers to the 13 Matched Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population

Percentage of participants with a \>=4-fold rise in serotype-specific pneumococcal OPA titers from before vaccination to 1 month after vaccination along with corresponding 2-sided 95% CIs were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

Time frame:
Before Vaccination 1 to 1 month after Vaccination 1
Reported as:
Number · percentage of participants
Percentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers to the 13 Matched Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population
percentage of participantsCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23
Serotype 172.1 (69.7 to 74.4)74.8 (72.4 to 77.0)
Serotype 356.1 (53.4 to 58.7)61.7 (59.1 to 64.2)
Serotype 475.5 (73.2 to 77.8)79.6 (77.4 to 81.7)
Serotype 555.6 (52.9 to 58.2)60.6 (58.0 to 63.2)
Serotype 6A80.5 (78.3 to 82.5)84.0 (82.0 to 85.9)
Serotype 6B75.7 (73.3 to 77.9)77.6 (75.3 to 79.8)
Serotype 7F71.8 (69.3 to 74.1)72.3 (69.8 to 74.6)
Serotype 9V67.7 (65.1 to 70.3)69.3 (66.7 to 71.8)
Serotype 1458.2 (55.5 to 60.8)54.0 (51.3 to 56.6)
Serotype 18C77.7 (75.4 to 79.8)79.6 (77.4 to 81.7)
Serotype 19A73.6 (71.3 to 75.9)77.5 (75.2 to 79.7)
Serotype 19F63.6 (61.1 to 66.2)66.9 (64.4 to 69.4)
Serotype 23F70.6 (68.2 to 73.0)74.4 (72.0 to 76.7)
SecondaryPercentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers for the 7 Additional Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1(20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2(PPSV23) in Cohort 1:E7-AIP

Percentage of participants with a \>=4-fold rise in serotype-specific pneumococcal OPA titers from before vaccination to 1 month after vaccination along with corresponding 2-sided 95% CIs were calculated for pneumococcal serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F.

Time frame:
Before Vaccination 1 to 1 month after Vaccination 1 for "Cohort 1: 20vPnC/Saline"; Before Vaccination 1 to 1 month after Vaccination 2 for "Cohort 1: 13vPnC/PPSV23"
Reported as:
Number · percentage of participants
Percentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers for the 7 Additional Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1(20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2(PPSV23) in Cohort 1:E7-AIP
percentage of participantsCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23
Serotype 877.8 (75.5 to 80.0)86.8 (84.8 to 88.6)
Serotype 10A75.5 (73.0 to 77.9)65.6 (62.8 to 68.4)
Serotype 11A59.2 (56.0 to 62.3)51.9 (48.7 to 55.0)
Serotype 12F87.4 (85.5 to 89.2)80.6 (78.1 to 82.8)
Serotype 15B77.8 (75.3 to 80.1)63.8 (61.0 to 66.6)
Serotype 22F82.7 (80.4 to 84.8)76.8 (74.3 to 79.2)
Serotype 33F60.1 (57.0 to 63.1)55.5 (52.4 to 58.5)
SecondaryPercentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers for the 20 Vaccines Serotypes From Before Vaccination to 1 Month After Vaccination in Cohort 2 and 3: Evaluable-20 Immunogenicity Population

Percentage of participants with a \>=4-fold rise in serotype-specific pneumococcal OPA titers from before vaccination to 1 month after vaccination along with corresponding 2-sided 95% CIs were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

Time frame:
Before vaccination to 1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers for the 20 Vaccines Serotypes From Before Vaccination to 1 Month After Vaccination in Cohort 2 and 3: Evaluable-20 Immunogenicity Population
percentage of participantsCohort 2: 20vPnCCohort 3: 20vPnC
Serotype 174.9 (69.8 to 79.6)86.0 (81.7 to 89.7)
Serotype 359.0 (53.4 to 64.5)56.7 (51.0 to 62.3)
Serotype 484.2 (79.6 to 88.1)91.4 (87.6 to 94.3)
Serotype 554.8 (49.1 to 60.4)64.8 (59.2 to 70.0)
Serotype 6A85.9 (81.5 to 89.6)96.7 (94.1 to 98.4)
Serotype 6B78.9 (73.9 to 83.4)89.2 (85.0 to 92.5)
Serotype 7F73.0 (67.6 to 77.9)76.1 (70.7 to 80.9)
Serotype 9V73.6 (68.1 to 78.6)84.0 (79.2 to 88.1)
Serotype 1462.3 (56.6 to 67.8)62.2 (56.4 to 67.8)
Serotype 18C82.5 (77.8 to 86.5)87.3 (83.0 to 90.8)
Serotype 19A80.0 (75.1 to 84.3)82.6 (77.8 to 86.7)
Serotype 19F64.2 (58.7 to 69.5)78.4 (73.4 to 82.8)
Serotype 23F81.2 (76.4 to 85.3)87.7 (83.5 to 91.1)
Serotype 879.4 (74.4 to 83.7)83.0 (78.3 to 87.1)
Serotype 10A78.8 (73.4 to 83.5)78.8 (73.4 to 83.6)
Serotype 11A61.0 (54.1 to 67.6)47.3 (40.5 to 54.1)
Serotype 12F93.2 (89.6 to 95.9)93.7 (89.9 to 96.3)
Serotype 15B82.5 (77.4 to 86.9)73.4 (67.4 to 78.8)
Serotype 22 F80.5 (75.1 to 85.1)83.8 (78.5 to 88.2)
Serotype 33F63.9 (57.4 to 70.1)60.6 (53.7 to 67.2)
SecondaryPercentage of Participants With Pneumococcal OPA Titers >= Lower Limit of Quantitation (LLOQ) for the 13 Matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population

The percentage of participants with OPA titers \>=LLOQ along with corresponding 2-sided 95% CIs were calculated 1 month after vaccination for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

Time frame:
1 month after Vaccination 1
Reported as:
Number · percentage of participants
Percentage of Participants With Pneumococcal OPA Titers >= Lower Limit of Quantitation (LLOQ) for the 13 Matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population
percentage of participantsCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23
Serotype 185.0 (83.0 to 86.8)87.9 (86.1 to 89.5)
Serotype 384.2 (82.2 to 86.0)87.0 (85.2 to 88.7)
Serotype 491.1 (89.5 to 92.5)92.1 (90.5 to 93.4)
Serotype 571.9 (69.5 to 74.3)76.0 (73.7 to 78.2)
Serotype 6A88.9 (87.1 to 90.5)90.9 (89.2 to 92.3)
Serotype 6B90.5 (88.9 to 92.0)91.6 (90.0 to 93.0)
Serotype 7F89.1 (87.3 to 90.7)91.3 (89.7 to 92.7)
Serotype 9V89.1 (87.4 to 90.7)90.3 (88.6 to 91.8)
Serotype 1491.6 (90.0 to 93.0)93.5 (92.1 to 94.8)
Serotype 18C93.8 (92.4 to 95.0)94.7 (93.4 to 95.8)
Serotype 19A96.3 (95.2 to 97.3)96.6 (95.5 to 97.5)
Serotype 19F80.3 (78.1 to 82.3)81.5 (79.3 to 83.5)
Serotype 23F82.1 (80.0 to 84.1)83.7 (81.6 to 85.6)
SecondaryPercentage of Participants With Pneumococcal OPA Titers >=LLOQ for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population

The percentage of participants with OPA titers \>=LLOQ along with corresponding 2-sided 95% CIs were calculated 1 month after vaccination for pneumococcal serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F.

Time frame:
1 month after Vaccination 1 in "Cohort 1: 20vPnC/Saline" or 1 month after Vaccination 2 in "Cohort 1: 13vPnC/PPSV23"
Reported as:
Number · percentage of participants
Percentage of Participants With Pneumococcal OPA Titers >=LLOQ for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population
percentage of participantsCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23
Serotype 892.9 (91.5 to 94.2)96.6 (95.5 to 97.5)
Serotype 10A95.6 (94.3 to 96.6)88.9 (87.1 to 90.6)
Serotype 11A97.7 (96.6 to 98.4)95.4 (94.0 to 96.5)
Serotype 12F95.7 (94.4 to 96.7)89.3 (87.4 to 91.0)
Serotype 15B94.1 (92.6 to 95.3)83.3 (81.1 to 85.3)
Serotype 22F98.6 (97.8 to 99.2)94.5 (93.0 to 95.7)
Serotype 33F96.4 (95.1 to 97.4)92.8 (91.2 to 94.2)
SecondaryPercentage of Participants With Pneumococcal OPA Titers >=LLOQ for the 20 Vaccines Serotypes at 1 Month After Vaccination (20vPnC) in Cohort 2 and 3: Evaluable-20 Immunogenicity Population

The percentage of participants with OPA titers \>=LLOQ along with corresponding 2-sided 95% CIs were calculated 1 month after vaccination for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. Data for this outcome measure were planned to be analyzed for the 20vPnC groups of Cohorts 2 and 3 only.

Time frame:
1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Pneumococcal OPA Titers >=LLOQ for the 20 Vaccines Serotypes at 1 Month After Vaccination (20vPnC) in Cohort 2 and 3: Evaluable-20 Immunogenicity Population
percentage of participantsCohort 2: 20vPnCCohort 3: 20vPnC
Serotype 187.2 (83.0 to 90.6)92.1 (88.5 to 94.8)
Serotype 387.4 (83.3 to 90.9)89.9 (86.0 to 93.0)
Serotype 494.0 (90.8 to 96.4)98.1 (95.9 to 99.3)
Serotype 572.8 (67.6 to 77.7)81.1 (76.3 to 85.2)
Serotype 6A91.8 (88.2 to 94.6)99.7 (98.2 to 100.0)
Serotype 6B95.3 (92.3 to 97.3)99.0 (97.2 to 99.8)
Serotype 7F92.7 (89.2 to 95.3)93.9 (90.6 to 96.3)
Serotype 9V92.6 (89.1 to 95.3)99.0 (97.2 to 99.8)
Serotype 1494.9 (91.8 to 97.1)99.1 (97.3 to 99.8)
Serotype 18C97.5 (95.1 to 98.9)98.1 (95.9 to 99.3)
Serotype 19A98.7 (96.8 to 99.7)99.7 (98.2 to 100.0)
Serotype 19F81.9 (77.2 to 85.9)95.2 (92.3 to 97.3)
Serotype 23F89.3 (85.4 to 92.5)96.5 (93.8 to 98.2)
Serotype 892.4 (88.8 to 95.0)95.8 (92.8 to 97.7)
Serotype 10A98.3 (96.1 to 99.4)100.0 (98.7 to 100.0)
Serotype 11A97.0 (94.3 to 98.7)99.6 (97.9 to 100.0)
Serotype 12F97.9 (95.6 to 99.2)98.5 (96.3 to 99.6)
Serotype 15B95.8 (92.7 to 97.8)96.8 (94.0 to 98.5)
Serotype 22F98.2 (95.9 to 99.4)99.6 (98.0 to 100.0)
Serotype 33F95.9 (92.7 to 97.9)99.6 (97.8 to 100.0)

Adverse events

Collected over Local reactions: within 10 days after Vaccination 1 (systematic assessment), Systemic events: within 7 days after Vaccination 1 (systematic assessment), Non serious AEs: up to 1 month after Vaccination 1, SAEs: up to 6 months after Vaccination 1. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: 20vPnC/Saline1/1,507 (0.1%)36/1,507 (2.4%)1,074/1,507 (71.3%)
Cohort 1: 13vPnC/PPSV230/1,490 (0%)29/1,490 (1.9%)1,063/1,490 (71.3%)
Cohort 2: 20vPnC0/334 (0%)1/334 (0.3%)281/334 (84.1%)
Cohort 2: 13vPnC0/111 (0%)1/111 (0.9%)91/111 (82%)
Cohort 3: 20vPnC0/335 (0%)2/335 (0.6%)302/335 (90.1%)
Cohort 3: 13vPnC0/112 (0%)1/112 (0.9%)107/112 (95.5%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23Cohort 2: 20vPnCCohort 2: 13vPnCCohort 3: 20vPnCCohort 3: 13vPnC
Skin bacterial infectionInfections and infestations0/15070/14900/3341/1110/3350/112
Herpes simplex meningitisInfections and infestations0/15070/14900/3340/1110/3351/112
NephrolithiasisRenal and urinary disorders0/15070/14901/3340/1110/3350/112
Ureteric obstructionRenal and urinary disorders0/15070/14901/3340/1110/3350/112
Acute myocardial infarctionCardiac disorders0/15071/14900/3340/1111/3350/112
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/15070/14900/3340/1111/3350/112
Coronary artery diseaseCardiac disorders3/15071/14900/3340/1110/3350/112
Cardiac failure congestiveCardiac disorders0/15072/14900/3340/1110/3350/112
AppendicitisInfections and infestations2/15070/14900/3340/1110/3350/112
CellulitisInfections and infestations2/15071/14900/3340/1110/3350/112
Most frequent other events
Showing 10 of 13
Most frequent other events
EventCohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23Cohort 2: 20vPnCCohort 2: 13vPnCCohort 3: 20vPnCCohort 3: 13vPnC
Injection site pain (PAIN)General disorders834/1507803/1490240/33477/111272/33592/112
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders588/1507553/1490165/33455/111223/33583/112
Fatigue (FATIGUE)General disorders454/1507455/1490130/33440/111143/33549/112
Headache (HEADACHE)Nervous system disorders324/1507345/1490107/33440/111130/33538/112
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders190/1507203/149051/33423/11145/33520/112
Injection site swelling (SWELLING)General disorders113/1507118/149029/33412/11139/33514/112
Injection site erythema (REDNESS)General disorders110/150792/149027/3346/11130/33511/112
Upper respiratory tract infectionInfections and infestations0/15070/14904/3343/1117/3351/112
InfluenzaInfections and infestations0/15070/14900/3340/1117/3351/112
NasopharyngitisInfections and infestations0/15070/14900/3340/1116/3352/112

Baseline characteristics

Safety population included all participants who received 1 dose of any of the following: 20vPnC, 13vPnC, PPSV23 or saline and had safety follow-up after any vaccination.

Age, Continuous
Age, Continuous(Years)Cohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23Cohort 2: 20vPnCCohort 2: 13vPnCCohort 3: 20vPnCCohort 3: 13vPnCTotal
Mean64.6 ± 4.8264.6 ± 4.8154.9 ± 2.7755.0 ± 3.1134.0 ± 8.7733.9 ± 8.0360.0 ± 11.15
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23Cohort 2: 20vPnCCohort 2: 13vPnCCohort 3: 20vPnCCohort 3: 13vPnCTotal
Female89787919569214772331
Male61061113942121351558
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23Cohort 2: 20vPnCCohort 2: 13vPnCCohort 3: 20vPnCCohort 3: 13vPnCTotal
Hispanic or Latino167169128247387
Not Hispanic or Latino132413083191013001023454
Unknown or Not Reported16133211348
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: 20vPnC/SalineCohort 1: 13vPnC/PPSV23Cohort 2: 20vPnCCohort 2: 13vPnCCohort 3: 20vPnCCohort 3: 13vPnCTotal
American Indian or Alaska Native69031120
Asian191510211158
Native Hawaiian or Other Pacific Islander1100316
Black or African American1772123515347480
White12951237278902741013275
More than one race79618132
Unknown or Not Reported27504018
08

Study locations

68 sites
  • Accel Research Sites
    Birmingham, Alabama 35216, United States
  • Coastal Clinical Research, Inc.
    Mobile, Alabama 36608, United States
  • East Valley Gastroenterology and Hepatology Associates
    Chandler, Arizona 85224, United States
  • The Pain Center of Arizona
    Peoria, Arizona 85381, United States
  • MedPharmics, LLC
    Phoenix, Arizona 85015, United States
  • HOPE Research Institute
    Phoenix, Arizona 85018, United States
  • The Pain Center of Arizona
    Phoenix, Arizona 85018, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Clinical Research Consulting, LLC
    Milford, Connecticut 06460, United States
  • Nature Coast Clinical Research
    Crystal River, Florida 34429, United States
  • Accel Research Sites - Clinical Research Unit
    DeLand, Florida 32720, United States
  • Research Centers of America, LLC
    Hollywood, Florida 33024, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Suncoast Research Group, LLC
    Miami, Florida 33135, United States
  • Acevedo Clinical Research Associates
    Miami, Florida 33142, United States
  • Qps-Mra, Llc
    South Miami, Florida 33143, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Meridian Clinical Research LLC
    Savannah, Georgia 31406, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Axtell Clinic, P.A.
    Newton, Kansas 67114, United States
  • Heartland Research Associates, LLC
    Newton, Kansas 67114, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67205, United States
  • Northwest Family Physicians
    Wichita, Kansas 67205, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Meridian Clinical Research, LLC
    Rockville, Maryland 20854, United States
  • Sundance Clinical Research
    Saint Louis, Missouri 63141, United States
  • Meridian Clinical Research, LLC
    Norfolk, Nebraska 68701, United States
  • Meridian Clinical Research LLC
    Omaha, Nebraska 68134, United States
  • ActivMed Practices & Research, Inc.
    Portsmouth, New Hampshire 03801, United States
  • United Medical Associates
    Binghamton, New York 13901, United States
  • Regional Clinical Research, Inc.
    Endwell, New York 13760, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • M3 Wake Research, Inc.
    Raleigh, North Carolina 27612, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45206, United States
  • Sterling Research Group, Ltd.
    Cincinnati, Ohio 45219, United States
  • Cincinnati Children's Hospital Medical Center (CCHMC)
    Cincinnati, Ohio 45229, United States
  • Sterling Research Group, Ltd.
    Cincinnati, Ohio 45246, United States
  • Rapid Medical Research, Inc.
    Cleveland, Ohio 44122, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Meridian Clinical Research, LLC
    Dakota Dunes, South Dakota 57049, United States
  • Tekton Research, Inc.
    Austin, Texas 78745, United States
  • Bellaire Doctor's Clinic
    Bellaire, Texas 77401, United States
  • Ventavia Research Group, LLC
    Fort Worth, Texas 76104, United States
  • Benchmark Research
    Fort Worth, Texas 76135, United States
  • HealthFirst Medical Group
    Fort Worth, Texas 76135, United States
  • Ventavia Research Group, LLC
    Keller, Texas 76248, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Ventavia Research Group, LLC
    Spring, Texas 77389, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Martin Diagnostic Clinic
    Tomball, Texas 77375, United States
  • J. Lewis Research Inc. / Foothill Family Clinic Draper
    Draper, Utah 84020, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • J. Lewis Research, Inc. - Jordan River Family Medicine
    South Jordan, Utah 84095, United States
  • Kaiser Permanente Washington Health Research Institute
    Seattle, Washington 98101, United States
  • Ladulaas Kliniska Studier
    Boras, 50630, Sweden
  • Infektionskliniken Malarsjukhuset
    Eskilstuna, 63188, Sweden
  • ProbarE i Lund
    Lund, 222 22, Sweden
  • Karolinska Trial Alliance, KTA Prim
    Stockholm, 113 61, Sweden
  • Akardo Med Site
    Stockholm, 114 46, Sweden
  • Akademiska Sjukhuset
    Uppsala, 75185, Sweden
  • Avdelningen för kliniska prövningar
    Örebro, 70362, Sweden
09

References and documents

Publications

  • Sabharwal C, Sundaraiyer V, Peng Y, Moyer L, Belanger TJ, Gessner BD, Jodar L, Jansen KU, Gruber WC, Scott DA, Watson W. Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease. Hum Vaccin Immunother. 2022 Nov 30;18(6):2126253. doi: 10.1080/21645515.2022.2126253. Epub 2022 Nov 11. PubMed 36368038 ↗
  • Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, Sundaraiyer V, Peng Y, Moyer L, Pride MW, Scully IL, Jansen KU, Gruber WC, Scott DA, Watson W. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged >/=18 Years. Clin Infect Dis. 2022 Aug 31;75(3):390-398. doi: 10.1093/cid/ciab990. Erratum In: Clin Infect Dis. 2024 Nov 22;79(5):1327. doi: 10.1093/cid/ciae389. PubMed 34940806 ↗
  • Mt-Isa S, Abderhalden LA, Musey L, Weiss T. Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20. Expert Rev Vaccines. 2022 Jan;21(1):115-123. doi: 10.1080/14760584.2021.1994858. Epub 2021 Oct 27. PubMed 34672224 ↗
  • Perdrizet J, Santana CFS, Senna T, Alexandre RF, Sini de Almeida R, Spinardi J, Wasserman M. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants. Hum Vaccin Immunother. 2021 Apr 3;17(4):1162-1172. doi: 10.1080/21645515.2020.1809266. Epub 2020 Sep 23. PubMed 32966176 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Dec 2019, 12 months.

Results were first posted in Dec 2020, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 12 months is close to that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2018
First posted
Nov 30, 2018
StartActual
Dec 12, 2018
Primary completionActual
Dec 16, 2019
CompletionActual
Dec 16, 2019
Results first posted
Dec 29, 2020
Last update
Dec 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03760146
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 30, 2018
Start date
Dec 12, 2018
Primary completion
Dec 16, 2019
Completion
Dec 16, 2019
Results posted
Dec 29, 2020
Last update
Dec 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion